34 related articles for article (PubMed ID: 29542782)
1. RVG-functionalized reduction sensitive micelles for the effective accumulation of doxorubicin in brain.
Xu J; Yang X; Ji J; Gao Y; Qiu N; Xi Y; Liu A; Zhai G
J Nanobiotechnology; 2021 Aug; 19(1):251. PubMed ID: 34419071
[TBL] [Abstract][Full Text] [Related]
2. BBB opening by low pulsed electric fields, depicted by delayed-contrast MRI, enables efficient delivery of therapeutic doxorubicin doses into mice brains.
Cooper I; Last D; Ravid O; Rand D; Matsree E; Omesi L; Shemesh C; Liberman M; Zach L; Furman O; Daniels D; Liraz-Zaltsman S; Mardor Y; Sharabi S
Fluids Barriers CNS; 2023 Sep; 20(1):67. PubMed ID: 37737197
[TBL] [Abstract][Full Text] [Related]
3. A D-Y Shaped Neuropeptide Y Mimetic Peptide-Dye Self-Assembly with Maximal Emission Beyond 1300 nm and Glioma Mitochondrial Activity Modulation.
Li Y; He X; Wang P; Yuan B; Pan Y; Hu X; Lu L; Wu A; Li J
Small; 2024 Mar; 20(13):e2308621. PubMed ID: 38109130
[TBL] [Abstract][Full Text] [Related]
4. Retracted: Preliminary Study on the Therapeutic Effect of Doxorubicin-Loaded Targeting Nanoparticles on Glioma.
And Biomechanics AB
Appl Bionics Biomech; 2023; 2023():9869251. PubMed ID: 37946836
[TBL] [Abstract][Full Text] [Related]
5. Neuropeptide Y Peptide Family and Cancer: Antitumor Therapeutic Strategies.
Sánchez ML; Rodríguez FD; Coveñas R
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373115
[TBL] [Abstract][Full Text] [Related]
6. Transformable Neuropeptide Prodrug with Tumor Microenvironment Responsiveness for Tumor Growth and Metastasis Inhibition of Triple-Negative Breast Cancer.
Cao Y; Ge X; Zhu X; Han Y; Wang P; Akakuru OU; Wu A; Li J
Adv Sci (Weinh); 2023 Jul; 10(21):e2300545. PubMed ID: 37147783
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapeutic nanomaterials in tumor boundary delineation: Prospects for effective tumor treatment.
Akakuru OU; Zhang Z; Iqbal MZ; Zhu C; Zhang Y; Wu A
Acta Pharm Sin B; 2022 Jun; 12(6):2640-2657. PubMed ID: 35755279
[TBL] [Abstract][Full Text] [Related]
8. Nanoparticle delivery systems for substance use disorder.
Kasina V; Mownn RJ; Bahal R; Sartor GC
Neuropsychopharmacology; 2022 Jul; 47(8):1431-1439. PubMed ID: 35351961
[TBL] [Abstract][Full Text] [Related]
9. Oncogenesis, Microenvironment Modulation and Clinical Potentiality of FAP in Glioblastoma: Lessons Learned from Other Solid Tumors.
Shi Y; Kong Z; Liu P; Hou G; Wu J; Ma W; Cheng X; Wang Y
Cells; 2021 May; 10(5):. PubMed ID: 34068501
[TBL] [Abstract][Full Text] [Related]
10. Peptides as a therapeutic avenue for nanocarrier-aided targeting of glioma.
Wanjale MV; Kumar GSV
Expert Opin Drug Deliv; 2017 Jun; 14(6):811-824. PubMed ID: 27690671
[TBL] [Abstract][Full Text] [Related]
11. Highlights in targeted nanoparticles as a delivery strategy for glioma treatment.
Luiz MT; Delello Di Filippo L; Tofani LB; de Araújo JTC; Dutra JAP; Marchetti JM; Chorilli M
Int J Pharm; 2021 Jul; 604():120758. PubMed ID: 34090991
[TBL] [Abstract][Full Text] [Related]
12. Y
Li J; Du Y; Jiang Z; Tian Y; Qiu N; Wang Y; Lqbal MZ; Hu M; Zou R; Luo L; Du S; Tian J; Wu A
Nanoscale; 2018 Mar; 10(13):5845-5851. PubMed ID: 29542782
[TBL] [Abstract][Full Text] [Related]
13. Liposome-based glioma targeted drug delivery enabled by stable peptide ligands.
Wei X; Gao J; Zhan C; Xie C; Chai Z; Ran D; Ying M; Zheng P; Lu W
J Control Release; 2015 Nov; 218():13-21. PubMed ID: 26428462
[TBL] [Abstract][Full Text] [Related]
14. Highly efficacious and specific anti-glioma chemotherapy by tandem nanomicelles co-functionalized with brain tumor-targeting and cell-penetrating peptides.
Zhu Y; Jiang Y; Meng F; Deng C; Cheng R; Zhang J; Feijen J; Zhong Z
J Control Release; 2018 May; 278():1-8. PubMed ID: 29596873
[TBL] [Abstract][Full Text] [Related]
15. A d-Peptide Ligand of Integrins for Simultaneously Targeting Angiogenic Blood Vasculature and Glioma Cells.
Ren Y; Zhan C; Gao J; Zhang M; Wei X; Ying M; Liu Z; Lu W
Mol Pharm; 2018 Feb; 15(2):592-601. PubMed ID: 29283582
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
